Cucurbitacin

Standard

Cucurbitacin : ancient compound shedding new light on cancer treatment. / Lee, Dhong Hyun; Iwanski, Gabriela B; Thoennissen, Nils H.

In: SCI WORLD J, Vol. 10, 2010, p. 413-8.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{8a5829f827f546bcaf934207f36fb37a,
title = "Cucurbitacin: ancient compound shedding new light on cancer treatment",
abstract = "Cucurbitacins and their derivatives are triterpenoids found in medicinal plants known for their diverse pharmacological and biological activities, including anticancer effects, throughout human history. Although initial attention to cucurbitacin as a potential anticancer drug withered for decades, recent discoveries showing that cucurbitacin is a strong STAT3 (Signal Transducers and Activators of Transcription-3) inhibitor have reclaimed the attention of the drug industry one more time. There is increasing evidence showing that some cucurbitacins not only inhibit the JAK-STAT pathway, but also affect other signaling pathways, such as the MAPK pathway, which are also known to be important for cancer cell proliferation and survival. Moreover, some reports have shown the synergistic effect of cucurbitacins with known chemotherapeutic agents, such as doxorubicin and gemcitabine. In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings.",
keywords = "Antineoplastic Agents, Cucurbitacins, Drug Screening Assays, Antitumor, Humans, MAP Kinase Signaling System, Neoplasms, Transcription Factors",
author = "Lee, {Dhong Hyun} and Iwanski, {Gabriela B} and Thoennissen, {Nils H}",
year = "2010",
doi = "10.1100/tsw.2010.44",
language = "English",
volume = "10",
pages = "413--8",
journal = "SCI WORLD J",
issn = "1537-744X",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Cucurbitacin

T2 - ancient compound shedding new light on cancer treatment

AU - Lee, Dhong Hyun

AU - Iwanski, Gabriela B

AU - Thoennissen, Nils H

PY - 2010

Y1 - 2010

N2 - Cucurbitacins and their derivatives are triterpenoids found in medicinal plants known for their diverse pharmacological and biological activities, including anticancer effects, throughout human history. Although initial attention to cucurbitacin as a potential anticancer drug withered for decades, recent discoveries showing that cucurbitacin is a strong STAT3 (Signal Transducers and Activators of Transcription-3) inhibitor have reclaimed the attention of the drug industry one more time. There is increasing evidence showing that some cucurbitacins not only inhibit the JAK-STAT pathway, but also affect other signaling pathways, such as the MAPK pathway, which are also known to be important for cancer cell proliferation and survival. Moreover, some reports have shown the synergistic effect of cucurbitacins with known chemotherapeutic agents, such as doxorubicin and gemcitabine. In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings.

AB - Cucurbitacins and their derivatives are triterpenoids found in medicinal plants known for their diverse pharmacological and biological activities, including anticancer effects, throughout human history. Although initial attention to cucurbitacin as a potential anticancer drug withered for decades, recent discoveries showing that cucurbitacin is a strong STAT3 (Signal Transducers and Activators of Transcription-3) inhibitor have reclaimed the attention of the drug industry one more time. There is increasing evidence showing that some cucurbitacins not only inhibit the JAK-STAT pathway, but also affect other signaling pathways, such as the MAPK pathway, which are also known to be important for cancer cell proliferation and survival. Moreover, some reports have shown the synergistic effect of cucurbitacins with known chemotherapeutic agents, such as doxorubicin and gemcitabine. In this review, we will summarize the recent discoveries regarding molecular mechanisms of action of cucurbitacins in human cancer cells and discuss the possibilities of cucurbitacin as a future anticancer drug in clinical settings.

KW - Antineoplastic Agents

KW - Cucurbitacins

KW - Drug Screening Assays, Antitumor

KW - Humans

KW - MAP Kinase Signaling System

KW - Neoplasms

KW - Transcription Factors

U2 - 10.1100/tsw.2010.44

DO - 10.1100/tsw.2010.44

M3 - SCORING: Journal article

C2 - 20209387

VL - 10

SP - 413

EP - 418

JO - SCI WORLD J

JF - SCI WORLD J

SN - 1537-744X

ER -